These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23768909)

  • 1. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
    Troxler T; Greenidge P; Zimmermann K; Desrayaud S; Drückes P; Schweizer T; Stauffer D; Rovelli G; Shimshek DR
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4085-90. PubMed ID: 23768909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
    Göring S; Taymans JM; Baekelandt V; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
    J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cinnoline-based inhibitors of LRRK2 kinase activity.
    Garofalo AW; Adler M; Aubele DL; Bowers S; Franzini M; Goldbach E; Lorentzen C; Neitz RJ; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Jan; 23(1):71-4. PubMed ID: 23219325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
    Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
    Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
    Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
    Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
    J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
    Salado IG; Zaldivar-Diez J; Sebastián-Pérez V; Li L; Geiger L; González S; Campillo NE; Gil C; Morales AV; Perez DI; Martinez A
    Eur J Med Chem; 2017 Sep; 138():328-342. PubMed ID: 28688273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
    Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
    Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.